RT Journal Article
SR Electronic
T1 Clinical Controversies in Psoriatic Disease: The Use of IL-17i/IL-23i Versus TNFi as First-line Advanced Therapy in Psoriatic Arthritis
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 26
OP 31
DO 10.3899/jrheum.211325
VO 49
IS 6 Suppl 1
A1 Deepak R. Jadon
A1 Arthur Kavanaugh
A1 Ying Ying Leung
YR 2022
UL http://www.jrheum.org/content/49/6_Suppl_1/26.abstract
AB Psoriatic arthritis (PsA) is a complex, heterogeneous disease, with disease activity in various domains. In recent years, many novel treatments with diverse mechanisms of action have been introduced into the clinical setting. Numerous factors go into the choice and sequencing of different therapies for individual patients. At the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting, a point/counterpoint debate was held addressing therapeutic choices. Specifically, the question addressed was whether interleukin (IL)-17/IL-23 inhibitors or tumor necrosis factor inhibitors are the appropriate initial therapy for patients with PsA.